Janssen makes the statement that getting its alternative scaffolds (Centyrins) into cells is easy. Rather, it has another problem. In order to solve this problem and 'expand the universe of druggable targets', Janssen is working with an academic/biotech consortium.
It would appear that the academic/biotech consortium holds the key to unlocking the intracellular space. Janssen and the Consortium are working on the frontier of science where success would be a therapeutic breakthrough.
Now, Janssen doesn't tell us who they are working with although from the context of the presentation it appears to rule out Aileron as well as other companies working with stapled peptides. The only surety would appear to be the use of endosomal escape peptides as a delivery vehicle.
The licencing of a endosomal escape peptide could be transformational for the future of drug development.
PYC Price at posting:
1.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)